** Shares of drugmaker Biogen BIIB.O rise 5.8% to $134 premarket
** Co lifts 2025 adjusted profit per share between $15.50 and $16.00, compared to prior expectations of $14.50 to $15.50
** Analysts expect 2025 profit of $14.68/share
** Co posts Q2 sales of $2.6 billion, above analysts' est of $2.32 billion - LSEG data
** Co reports Q2 profit of $5.47/share, above estimates of $3.86/share
** As of last close, stock down 17% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。